# Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT01076556** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Prolymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage I Small Lymphocytic Lymphoma
- Stage II Chronic Lymphocytic Leukemia
- Stage II Small Lymphocytic Lymphoma
- Stage III Chronic Lymphocytic Leukemia
- Stage III Small Lymphocytic Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Alvocidib Hydrochloride
- **DRUG:** Cyclophosphamide
- **OTHER:** Diagnostic Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01076556
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076556, "Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01076556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*